The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis
- PMID: 38199397
- DOI: 10.1016/j.jad.2024.01.066
The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis
Abstract
Background: Premenstrual dysphoric disorder is characterised by symptoms confined to the premenstrual phase of the menstrual cycle. Confirmed diagnosis requires prospective monitoring of symptoms over two cycles, otherwise the diagnosis is provisional. We aimed to measure the point prevalence of premenstrual dysphoric disorder.
Methods: We searched for studies of prevalence using MEDLINE, EMBASE, PsycINFO and PubMed. For each study, the total sample size and number of cases were extracted. The prevalence across studies was calculated using random effects meta-analysis with a generalised linear mixed model. Potential sources of heterogeneity were explored by meta-regression and subgroup analyses. Pre-registration was with PROSPERO (CRD42021249249).
Results: 44 studies with 48 independent samples met inclusion criteria, consisting of 50,659 participants. The pooled prevalence was 3.2 % (95 % confidence intervals: 1.7 %-5.9 %) for confirmed and 7.7 % (95 % confidence intervals: 5.3 %-11.0 %) for provisional diagnosis. There was high heterogeneity across all studies (I2 = 99 %). Sources of heterogeneity identified by meta-regression were continent of sample (p < 0.0001), type of sample (community-based, university, high school) (p = 0.007), risk of bias (p = 0.009), and method of diagnosis (p = 0.017). Restricting the analysis to community-based samples using confirmed diagnosis resulted in a prevalence of 1.6 % (95 % confidence intervals: 1.0 %-2.5 %), with low heterogeneity (I2 = 26 %).
Limitations: A small number of included studies used full DSM criteria in community settings.
Conclusions: The point prevalence of premenstrual dysphoric disorder using confirmed diagnosis is lower compared with provisional diagnosis. Studies relying on provisional diagnosis are likely to produce artificially high prevalence rates.
Keywords: Depressive disorders; Epidemiology; Meta-analysis; Premenstrual dysphoric disorder; Premenstrual syndrome.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest We declare no competing interests.
Similar articles
-
Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD010503. doi: 10.1002/14651858.CD010503.pub2. Cochrane Database Syst Rev. 2017. PMID: 28257559 Free PMC article.
-
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder.Cochrane Database Syst Rev. 2024 Aug 14;8(8):CD001396. doi: 10.1002/14651858.CD001396.pub4. Cochrane Database Syst Rev. 2024. PMID: 39140320 Free PMC article.
-
Selective serotonin reuptake inhibitors for premenstrual syndrome.Cochrane Database Syst Rev. 2013 Jun 7;2013(6):CD001396. doi: 10.1002/14651858.CD001396.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2024 Aug 14;8:CD001396. doi: 10.1002/14651858.CD001396.pub4. PMID: 23744611 Free PMC article. Updated.
-
Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS).Cochrane Database Syst Rev. 2025 Jun 10;6(6):CD011330. doi: 10.1002/14651858.CD011330.pub2. Cochrane Database Syst Rev. 2025. PMID: 40492482 Review.
-
A systematic review and meta-analysis on the comorbidity of premenstrual dysphoric disorder or premenstrual syndrome with mood disorders: prevalence, clinical and neurobiological correlates.Br J Psychiatry. 2025 Jul 11:1-14. doi: 10.1192/bjp.2025.133. Online ahead of print. Br J Psychiatry. 2025. PMID: 40641141 Review.
Cited by
-
Tracking mood symptoms across the menstrual cycle in women with depression using ecological momentary assessment and heart rate variability.BMJ Ment Health. 2025 Jun 24;28(1):e301674. doi: 10.1136/bmjment-2025-301674. BMJ Ment Health. 2025. PMID: 40555545 Free PMC article.
-
Transcription of GABAA receptor subunits in circulating monocytes and association to emotional brain function in premenstrual dysphoric disorder.Transl Psychiatry. 2025 Jul 23;15(1):255. doi: 10.1038/s41398-025-03465-6. Transl Psychiatry. 2025. PMID: 40701967 Free PMC article.
-
(S)-S-adenosylmethionine in the treatment of pre-menstrual disorders in adult women: A protocol for an open-label pilot study.Contemp Clin Trials Commun. 2024 Mar 30;39:101297. doi: 10.1016/j.conctc.2024.101297. eCollection 2024 Jun. Contemp Clin Trials Commun. 2024. PMID: 38590512 Free PMC article.
-
Examining the impact of premenstrual dysphoric disorder (PMDD) on life and relationship quality: An online cross-sectional survey study.PLoS One. 2025 Apr 23;20(4):e0322314. doi: 10.1371/journal.pone.0322314. eCollection 2025. PLoS One. 2025. PMID: 40267093 Free PMC article.
-
Circadian attributes of neurological and psychiatric disorders as basis for their medication chronotherapy.Adv Drug Deliv Rev. 2025 Aug;223:115576. doi: 10.1016/j.addr.2025.115576. Epub 2025 Apr 3. Adv Drug Deliv Rev. 2025. PMID: 40187645 Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous